Merck and SKKU Institute of Quantum Biophysics Sign MoU for In-depth Scientific Collaboration
News Release
- The signing of MoU marks steps towards the first industry-academia collaboration for Merck quantum biophysics medicines in South Korea
Seoul, South Korea, December 13, 2021 – Merck, a leading science and technology company, today announced it has signed a non-binding Memorandum of Understanding (MoU) with the Institute of Quantum Biophysics, Sung Kyun Kwan University (SKKU), South Korea, outlining its planned support of the development of diagnostics and therapeutic solutions based on quantum biophysics theory and phenomena.
The signing ceremony, held at Sung Kyun Kwan University in Suwon, was attended by Nam-Koo Lee of Merck and Professors Luke P. Lee and Han-Sang Cho, both of the Institute of Quantum Biophysics, SKKU.
Under this partnership, Merck plans to offer seminars and training programs to promote the exchange of knowledge and information, as well as provide scholarship and internship programs to support local talent development in bioscience.
“Quantum biophysics is an up-and-coming research field and is expected to have a significant impact on advancing life science and precision medicine for its ability to create a computer model of predictions within extremely large data sets,” said Stephen Nam-Koo Lee, Head of Research Solutions for Korea & Taiwan, Life Science business sector, Merck Korea. “We are committed to working closely with academia to support the products and services needed for this research.”
“The Institute of Quantum Biophysics aims to facilitate collaborative and interdisciplinary research efforts among researchers in basic science, engineering, and medicine to develop innovative quantum technologies for medicines,” said Prof. Luke P. Lee, the Institute of Quantum Biophysics, SKKU. “With Merck’s technology and know-how, we will be better positioned to produce outcomes that can advance modern medicine.”
About Merck
Merck, a leading science and technology company, operates across healthcare, life science, and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
To continue reading please sign in or create an account.
Don't Have An Account?